Core Viewpoint - The financial performance of Di Rui Medical has significantly declined in the first three quarters of 2025, with a revenue drop of 60.12% and a net profit loss of 87.25 million yuan, reflecting challenges in the domestic market and the impact of industry competition and pricing policies [1][2]. Financial Performance - The company's revenue for the first three quarters was 469 million yuan, a decrease of 60.12% year-on-year [1]. - The net profit attributable to shareholders was -87.25 million yuan, representing a year-on-year decline of 145.31% [1]. Strategic Adjustments - Di Rui Medical is focusing on risk mitigation, stability, and industrial development, which includes optimizing the board structure and adjusting the management team to include individuals with operational backgrounds [1]. - The company has clarified its R&D direction and areas of focus, aiming to fulfill the digitalization and intelligence responsibilities of the China Resources medical industry [1]. Market Expansion - The company is pursuing a dual-driven strategy for domestic and international markets, emphasizing localized management and product upgrades [1]. - Di Rui Medical has achieved some success in international markets, with several high-speed models registered in various countries, including India, the Philippines, and Turkey, showing year-on-year growth [1]. Domestic Market Challenges - The domestic market is under pressure due to competition and centralized procurement policies affecting reagent prices, prompting the company to adjust pricing policies and optimize performance assessments [2]. - The company plans to conduct a "100-day offensive" campaign in the fourth quarter to enhance performance and overcome challenges [2]. Shareholder Developments - The controlling shareholder, Huade Xinrun, has released a pledge on 45.6 million shares, which accounts for 59% of its holdings and 16.72% of the company's total share capital, resulting in no pledged shares remaining [2].

Group 1: AI and Health Innovation - The rapid development of AI technology is driving transformation in the healthcare sector, with a focus on proactive health management through a new model combining offline infrared detection and online AI health records [1] - The launch of the world's first health forecasting AI digital asset marks a significant step in establishing a credible health service path that integrates health screening, clinical diagnosis, and management [1] - The innovative model addresses the information gap between health screening and clinical diagnosis, creating a comprehensive health service pathway from warning to management [1] Group 2: Company Performance and Strategy - In the first three quarters of 2025, the company reported a revenue of 469 million yuan, a decrease of 60.12% year-on-year, and a net profit attributable to shareholders of -87.25 million yuan, down 145.31% [3] - The company's performance is under pressure primarily due to the domestic market, influenced by competition and price adjustments in the in vitro diagnostic industry [3] - The company is implementing a "100-day offensive" initiative in the fourth quarter to enhance performance and overcome challenges [3] Group 3: Technological Advancements - The company has developed an intelligent recognition system for urine analysis, utilizing AI and deep learning to improve diagnostic capabilities [2] - The system employs a multi-layer convolutional neural network (CNN) architecture trained on a large dataset of clinical urine samples, enhancing the identification of various pathological components [2] - Innovative techniques such as transfer learning and data augmentation have been introduced to address challenges in medical imaging, improving the model's ability to recognize low-frequency pathological features [2]

迪瑞医疗科技股份有限公司（以下简称"公司"）《2025 年第三季度报告》 于 2025 年 10 月 28 日在中国证监会指定的创业板信息披露网站上披露。为便于 投资者进一步了解公司的生产经营等情况，公司拟定于 2025 年 10 月 28 日（星 期二）15：00 至 16：30 采取网络远程的方式举办 2025 年第三季度报告网上业 绩说明会。 投资者参与本次业绩说明会具体方式如下： 1、时间：2025 年 10 月 28 日（星期二）15：00 至 16：30； 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-051 2、参与方式：投资者可登录全景网"投资者关系互动平台"（https://ir.p5w.net） 参与本次业绩说明会。 迪瑞医疗科技股份有限公司 出席本次网上业绩说明会的人员有：公司副总经理、财务总监张兴艳女士， 董事、副总经理、董事会秘书安国柱先生（如有特殊情况，参与人员会有调整）。 关于举行 2025 年第三季度报告网上业绩说明会的公告 欢迎广大投资者积极参与。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司《2025 年第三季度报告》于 2025 年 10 月 28 日 在中国证监会指定的创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上 披露，敬请投资者注意查阅。 特此公告。 迪瑞医疗科技股份有限公司董事会 2025 年 10 月 27 日 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-050 迪瑞医疗科技股份有限公司 2025 年第三季度报告披露提示性公告 ...

Financial Performance - Revenue for Q3 2025 was CNY 118,056,019.80, a decrease of 60.27% compared to the same period last year[5] - Net profit attributable to shareholders was CNY -58,941,976.28, a decline of 315.63% year-on-year[5] - The company reported a basic and diluted earnings per share of CNY -0.2161, down 315.67% from the previous year[5] - Total operating revenue for the current period was ¥468,750,514.30, a significant decrease from ¥1,175,445,053.92 in the previous period, representing a decline of approximately 60%[35] - Operating profit for the current period was a loss of ¥93,467,863.32, compared to a profit of ¥214,106,161.38 in the previous period[36] - Net profit for the current period was a loss of ¥87,253,663.92, contrasting with a net profit of ¥192,566,604.72 in the previous period[36] - The total comprehensive income for the period attributable to the parent company was -82,064,717.11 yuan, compared to 193,444,937.30 yuan in the previous period[37] - The basic and diluted earnings per share for the current period were both -0.3200 yuan, down from 0.7062 yuan in the previous period[37] Cash Flow - Cash flow from operating activities showed a net outflow of CNY -58,210,987.00, an increase of 80.56% in outflow compared to the previous year[5] - The net cash flow from operating activities increased by CNY 241.16 million, a growth of 80.56%, mainly due to reduced procurement payments and controlled operating expenses[24] - Cash inflows from operating activities totaled 708,497,319.40 yuan, a decrease of 22.2% from 911,446,107.42 yuan in the previous period[38] - Cash outflows from operating activities amounted to 766,708,306.40 yuan, down from 1,210,818,059.95 yuan in the previous period[39] - The net cash flow from operating activities was -58,210,987.00 yuan, an improvement from -299,371,952.53 yuan in the previous period[39] - The net cash flow from investing activities decreased by CNY 272.69 million, a decline of 3627.79%, primarily due to increased cash payments for purchasing structured deposits[24] - The net cash flow from investing activities was -265,176,908.77 yuan, compared to a positive cash flow of 7,516,792.34 yuan in the previous period[39] - The net cash flow from financing activities increased by CNY 58.83 million, a growth of 64.45%, mainly due to a decrease in dividend payments compared to the previous year[24] - Cash inflows from financing activities were 425,000,000.00 yuan, significantly higher than 115,000,000.00 yuan in the previous period[39] - The net cash flow from financing activities was -32,445,646.99 yuan, an improvement from -91,270,818.77 yuan in the previous period[39] Assets and Liabilities - Total assets decreased by 10.38% to CNY 2,784,841,089.87 compared to the end of the previous year[5] - Total assets decreased to ¥2,784,841,089.87 from ¥3,107,533,388.27, reflecting a decline of approximately 10.4%[33] - Total liabilities decreased to ¥889,037,469.80 from ¥1,058,764,060.35, showing a reduction of about 16%[33] - Current liabilities totaled ¥478,180,089.99, down from ¥697,309,012.71, indicating a decrease of approximately 31.4%[33] - Non-current assets decreased to ¥1,074,164,186.50 from ¥1,263,422,546.45, representing a decline of about 15%[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,848[27] - The largest shareholder, Shenzhen Huadexin Run Equity Investment Enterprise, holds 28.34% of shares, amounting to 77,288,400 shares, with 45,600,156 shares pledged[28] Operational Adjustments - The company adjusted pricing policies for key models in response to market competition, impacting short-term sales and profits[8] - The company experienced a 60.12% decrease in operating income due to market environment impacts and business model adjustments[20] - The company aims to conduct a "100-day campaign" in Q4 to improve performance and address challenges[8] - The company reported a significant increase in cash flow from operations, indicating improved operational efficiency and cost control measures[24] Other Financial Metrics - Financial expenses decreased by 610.54% due to increased interest income from maturing structured deposits[21] - Research and development expenses were ¥74,028,362.03, down from ¥95,643,187.59, indicating a reduction of approximately 22.6%[36] - Other comprehensive income after tax for the current period was ¥5,189,997.93, compared to ¥867,601.54 in the previous period, showing a significant increase[36] - The total amount of cash and cash equivalents at the end of the reporting period was CNY 235.01 million, down from CNY 586.68 million at the beginning of the period[31] - The accounts receivable decreased from CNY 441.69 million at the beginning of the period to CNY 335.81 million at the end of the period[31] - The company had a total of 436,936 restricted shares at the end of the reporting period, with 16,382 shares released from restrictions during the period[29] Audit Status - The company’s third-quarter financial report was not audited[41]

Company Overview - Diyi Medical Technology Co., Ltd. is located in Changchun, Jilin Province, and was established on December 26, 1994. The company was listed on September 10, 2014. Its main business involves the research, production, and sales of medical testing instruments and related test paper reagents [1][2]. Financial Performance - As of June 30, 2025, Diyi Medical reported a revenue of 351 million yuan, a year-on-year decrease of 60.07%. The net profit attributable to shareholders was -28.31 million yuan, representing a year-on-year decline of 117.13% [2]. - The company has cumulatively distributed 923 million yuan in dividends since its A-share listing, with 340 million yuan distributed over the past three years [3]. Stock Performance - On October 27, Diyi Medical's stock price fell by 2.02%, trading at 13.60 yuan per share, with a total market capitalization of 3.709 billion yuan. The stock has decreased by 15.42% year-to-date, with a 2.03% increase over the last five trading days, a 1.73% decrease over the last 20 days, and a 7.48% decrease over the last 60 days [1]. - The number of shareholders as of June 30, 2025, was 18,000, an increase of 0.77% from the previous period, while the average circulating shares per person decreased by 0.77% to 15,114 shares [2]. Capital Flow - In terms of capital flow, there was a net outflow of 6.888 million yuan from major funds, with no significant purchases from large orders. The selling pressure included 2.6866 million yuan from large orders, accounting for 10.98% of the total [1].

Group 1 - The core viewpoint of the articles highlights the recent trends in stock recommendations and target price adjustments by brokerages from October 20 to October 26, indicating significant movements in the market [1][2]. Group 2 - During the period, brokerages issued a total of 326 target price adjustments, with notable increases for Zhongrun Optical and Guibao Pet, showing target price increases of 74.39% and 66.37% respectively, belonging to the computer equipment and feed industries [1]. - A total of 381 listed companies received brokerage recommendations, with Yanjing Beer receiving the highest number at 21 recommendations, followed by Ningde Times with 20 and Runben Co. with 18 [1]. - Five companies had their ratings upgraded, including Huatai Securities raising Shuangliang Energy's rating from "Hold" to "Buy," and Huayuan Securities upgrading Huayou Cobalt from "Hold" to "Buy" [1]. - Conversely, five companies experienced rating downgrades, such as Zhongyou Securities lowering Shenma Power's rating from "Buy" to "Hold," and Tianfeng Securities downgrading Dirui Medical from "Buy" to "Hold" [1]. Group 3 - In terms of initial coverage, brokerages provided 65 first-time ratings, with Yanjiang Co. receiving a "Buy" rating from Tianfeng Securities, and Qianfang Technology and Zhongyao Holdings both receiving "Buy" ratings from Dongwu Securities [2]. - Other companies like Yingluohua and Yipuli also received ratings, with Yingluohua getting an "Increase" rating from Hualong Securities and Yipuli a "Buy" rating from Global Fortune Management [2].

Group 1 - The core point of the article is that Dirui Medical (SZ 300396) held a temporary board meeting on October 24, 2025, to discuss the adjustment of the audit committee members [1] - For the first half of 2025, Dirui Medical's revenue composition was 99.37% from medical devices and 0.63% from other businesses [1] - As of the time of reporting, Dirui Medical's market capitalization was 3.8 billion yuan [1] Group 2 - The article also highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a hot secondary market in biomedicine [1] - There is a contrast noted between the thriving secondary market and the cooling fundraising environment in the primary market for biomedicine [1]

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-046 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更前次股东大会决议； 一、会议召开和出席情况 公司于 2025 年 09 月 30 日发出《关于召开 2025 年第二次临时股东大会的通 知》（详见中国证监会指定的创业板信息披露网站 http://www.cninfo.com.cn）。 1、会议召开时间：2025 年 10 月 24 日 14:40 2、会议召开地点：公司会议室 3、会议召开方式：采取现场投票与网络投票相结合的方式。现场会议召开 时间：2025 年 10 月 24 日（星期五）14:40。网络投票时间：2025 年 10 月 24 日。 其中，通过交易系统进行网络投票的时间为：2025 年 10 月 24 日（星期五） 9:15—9:25、9:30-11:30 和 13:00—15:00；通过互联网投票系统投票的具体时间为： 2025 年 10 月 24 日（星期五）09:15 至 15:00 期间的 ...

公司董事会收到董事、审计委员会委员倪冰先生关于辞去审计委员会委员的 辞职报告，倪冰先生因工作安排原因申请辞去公司第六届董事会审计委员会委员， 辞去审计委员会委员后仍继续担任公司第六届董事会非独立董事。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-048 迪瑞医疗科技股份有限公司 第六届董事会第五次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届董事会第五次临时 会议（以下简称"本次会议"）于 2025 年 10 月 24 日在公司以现场结合通讯方式 召开，会议通知已于 2025 年 10 月 24 日以口头和电子邮件的方式发出，经全体 董事一致同意豁免本次董事会通知时限。本次会议由董事长郭霆先生主持，应出 席公司会议的董事 9 人，实际出席公司会议的董事 9 人，公司高级管理人员列席 会议。会议召开符合《中华人民共和国公司法》、《公司章程》的规定，会议合法 有效。 二、会议审议情况 与会董事经认真审议，以现场结合通讯表决方式审议通过了如下决议： 1、审议并 ...